Regulation of circulating endocannabinoids associated with cancer and metastases in mice and humans

Oncoscience

Volumn 1, Issue 4, 2014, Pages 272-282

  Sailler, Sebastian ^a   Schmitz, Katja ^a   Jäger, Elke ^b   Ferreiros, Nerea ^a   Wicker, Sabine ^a   Zschiebsch, Katja ^a   Pickert, Geethanjali ^a   Geisslinger, Gerd ^a   Walter, Carmen ^a   Tegeder, Irmgard ^a   Lötsch, Jörn ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b KRANKENHAUS NORDWEST   (Germany)

Author keywords

Cannabinoids; Human; Metastasis; Mice

Indexed keywords

EID: 84938505261     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.30     Document Type: Article

References (45)

1. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC and Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346(6284): 561-564.
2. Yin H, Chu A, Li W, Wang B, Shelton F, Otero F, Nguyen DG, Caldwell JS and Chen YA. Lipid G protein-coupled receptor ligand identification using beta-arrestin PathHunter assay. J Biol Chem. 2009; 284(18): 12328-12338.
3. O'Sullivan SE. Cannabinoids go nuclear: evidence for activation of peroxisome proliferator-activated receptors. Br J Pharmacol. 2007; 152(5): 576-582.
4. Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M, Vogel Z and De Petrocellis L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem J. 2001; 358(Pt 1): 249-255.
5. Grimaldi C and Capasso A. The endocannabinoid system in the cancer therapy: an overview. Current medicinal chemistry. 2011; 18(11): 1575-1583.
6. Guindon J and Hohmann AG. The endocannabinoid system and cancer: therapeutic implication. British journal of pharmacology. 2011; 163(7): 1447-1463.
7. Bifulco M, Laezza C, Gazzerro P and Pentimalli F. Endocannabinoids as emerging suppressors of angiogenesis and tumor invasion (review). Oncology reports. 2007; 17(4): 813-816.
8. Cabral GA, Toney DM, Fischer-Stenger K, Harrison MP and Marciano-Cabral F. Anandamide inhibits macrophagemediated killing of tumor necrosis factor-sensitive cells. Life Sci. 1995; 56(23-24): 2065-2072.
9. Klegeris A, Bissonnette CJ and McGeer PL. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol. 2003; 139(4): 775-786.
10. Correa F, Hernangomez M, Mestre L, Loria F, Spagnolo A, Docagne F, Di Marzo V and Guaza C. Anandamide enhances IL-10 production in activated microglia by targeting CB(2) receptors: roles of ERK1/2, JNK, and NFkappaB. Glia. 2010; 58(2): 135-147.
11. Eisenstein TK, Meissler JJ, Wilson Q, Gaughan JP and Adler MW. Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. J Neuroimmunol. 2007; 189(1-2): 17-22.
12. Kishimoto S, Kobayashi Y, Oka S, Gokoh M, Waku K and Sugiura T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. J Biochem. 2004; 135(4): 517-524.
13. Joseph J, Niggemann B, Zaenker KS and Entschladen F. Anandamide is an endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer Immunol Immunother. 2004; 53(8): 723-728.
14. Ramer R and Hinz B. Inhibition of cancer cell invasion by cannabinoids via increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl Cancer Inst. 2008; 100(1): 59-69.
15. Caffarel MM, Andradas C, Mira E, Perez-Gomez E, Cerutti C, Moreno-Bueno G, Flores JM, Garcia-Real I, Palacios J, Manes S, Guzman M and Sanchez C. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer. 2010; 9: 196.
16. Preet A, Qamri Z, Nasser MW, Prasad A, Shilo K, Zou X, Groopman JE and Ganju RK. Cannabinoid receptors, CB1 and CB2, as novel targets for inhibition of non-small cell lung cancer growth and metastasis. Cancer Prev Res (Phila). 2011; 4(1): 65-75.
17. Diaz-Laviada I. The endocannabinoid system in prostate cancer. Nat Rev Urol. 2011; 8(10): 553-561.
18. Endsley MP, Thill R, Choudhry I, Williams CL, Kajdacsy-Balla A, Campbell WB and Nithipatikom K. Expression and function of fatty acid amide hydrolase in prostate cancer. Int J Cancer. 2008; 123(6): 1318-1326.
19. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, Pacher P, Schon MR, Jordan J and Stumvoll M. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes. 2006; 55(11): 3053-3060.
20. Rodriguez LG, Wu X and Guan J-L. Wound-healing assay. Methods Mol Biol. 2005; 294: 23-29.
21. Walter C, Ferreiros N, Bishay P, Geisslinger G, Tegeder I and Lötsch J. Exogenous delta-9-tetrahydrocannabinol influences circulating endogenous can-nabinoids in humans. In J Psychopharmacol. 2012; (accepted).
22. Kingsley PJ and Marnett LJ. Analysis of endocannabinoids by Ag+ coordination tandem mass spectrometry. Analytical biochemistry. 2003; 314(1): 8-15.
23. Glaser ST and Kaczocha M. Cyclooxygenase-2 mediates anandamide metabolism in the mouse brain. The Journal of pharmacology and experimental therapeutics. 2010; 335(2): 380-388.
24. Rouzer CA and Marnett LJ. Endocannabinoid oxygenation by cyclooxygenases, lipoxygenases, and cytochromes P450: cross-talk between the eicosanoid and endocannabinoid signaling pathways. Chem Rev. 2011; 111(10): 5899-5921.
25. Di Marzo V, Melck D, Orlando P, Bisogno T, Zagoory O, Bifulco M, Vogel Z and De Petrocellis L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. The Biochemical journal. 2001; 358(Pt 1): 249-255.
26. Ligresti A, Bisogno T, Matias I, De Petrocellis L, Cascio MG, Cosenza V, D'Argenio G, Scaglione G, Bifulco M, Sorrentini I and Di Marzo V. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. 2003; 125(3): 677-687.
27. Michalski CW, Oti FE, Erkan M, Sauliunaite D, Bergmann F, Pacher P, Batkai S, Muller MW, Giese NA, Friess H and KleeffJ. Cannabinoids in pancreatic cancer: correlation with survival and pain. International journal of cancer Journal international du cancer. 2008; 122(4): 742-750.
28. Thors L, Bergh A, Persson E, Hammarsten P, Stattin P, Egevad L, Granfors T and Fowler CJ. Fatty acid amide hydrolase in prostate cancer: association with disease severity and outcome, CB1 receptor expression and regulation by IL-4. PloS one. 2010; 5(8): e12275.
29. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK and Sethi G. Inflammation and cancer: how hot is the link? Biochemical pharmacology. 2006; 72(11): 1605-1621.
30. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD and DuBois RN. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. The Journal of clinical investigation. 1997; 99(9): 2254-2259.
31. Bishay P, Schmidt H, Marian C, Haussler A, Wijnvoord N, Ziebell S, Metzner J, Koch M, Myrczek T, Bechmann I, Kuner R, Costigan M, Dehghani F, Geisslinger G and Tegeder I. R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids. PloS one. 2010; 5(5): e10628.
32. Wechter WJ, Leipold DD, Murray ED, Jr., Quiggle D, McCracken JD, Barrios RS and Greenberg NM. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res. 2000; 60(8): 2203-2208.
33. Hamtiaux L, Masquelier J, Muccioli GG, Bouzin C, Feron O, Gallez B and Lambert DM. The association of N-palmitoylethanolamine with the FAAH inhibitor URB597 impairs melanoma growth through a supraadditive action. BMC cancer. 2012; 12: 92.
34. Endsley MP, Aggarwal N, Isbell MA, Wheelock CE, Hammock BD, Falck JR, Campbell WB and Nithipatikom K. Diverse roles of 2-arachidonoylglycerol in invasion of prostate carcinoma cells: Location, hydrolysis and 12-lipoxygenase metabolism. International journal of cancer Journal international du cancer. 2007; 121(5): 984-991.
35. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MCG, Ward AM, Hahn YK, Lichtman AH, Conti B and Cravatt BF. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science. 2011; 334(6057): 809-813.
36. Fulton AM, Ma X and Kundu N. Targeting prostaglandin E EP receptors to inhibit metastasis. Cancer Res. 2006; 66(20): 9794-9797.
37. Kim R, Emi M and Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007; 121(1): 1-14.
38. Blaukat A, Barac A, Cross MJ, Offermanns S and Dikic I. G protein-coupled receptor-mediated mitogen-activated protein kinase activation through cooperation of Galpha(q) and Galpha(i) signals. Mol Cell Biol. 2000; 20(18): 6837-6848.
39. Tegeder I and Geisslinger G. Opioids as modulators of cell death and survival-unraveling mechanisms and revealing new indications. Pharmacol Rev. 2004; 56(3): 351-369.
40. Grommes C, Karlo JC, Caprariello A, Blankenship DA, Dechant A and Landreth GE. The PPARγ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model. Cancer chemotherapy and pharmacology. 2013; 71(4): 929-936.
41. Pang X, Wei Y, Zhang Y, Zhang M, Lu Y and Shen P. Peroxisome proliferator-activated receptor-γ activation inhibits hepatocellular carcinoma cell invasion by upregulating plasminogen activator inhibitor-1. Cancer Sci. 2013; 104(6): 672-680.
42. Hu G, Ren G and Shi Y. The putative cannabinoid receptor GPR55 promotes cancer cell proliferation. Oncogene. 2011; 30(2): 139-141.
43. Nasser MW, Qamri Z, Deol YS, Smith D, Shilo K, Zou X and Ganju RK. Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PLoS One. 2011; 6(9): e23901.
44. Fanelli F, Di Lallo VD, Belluomo I, De Iasio R, Baccini M, Casadio E, Gasparini DI, Colavita M, Gambineri A, Grossi G, Vicennati V, Pasquali R and Pagotto U. Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS. J Lipid Res. 2012; 53(3): 481-493.
45. Banni S, Carta G, Murru E, Cordeddu L, Giordano E, Sirigu AR, Berge K, Vik H, Maki KC, Di Marzo V and Griinari M. Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects. Nutrition & metabolism. 2011; 8(1): 7.